{"id":"W2146161922","doi":"10.1056/nejmoa043116","title":"Capecitabine as Adjuvant Treatment for Stage III Colon Cancer","year":2005,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1247,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Capecitabine; Medicine; Fluorouracil; Hazard ratio; Internal medicine; Colorectal cancer; Regimen; Clinical endpoint; Bolus (digestion); Adverse effect; Gastroenterology; Oncology; Adjuvant; Surgery; Confidence interval; Chemotherapy; Cancer; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003134431,0.0001716421,0.0004408283,0.0001495244,0.000112073,0.0001649685,0.0001210298,0.0001512498,0.001867402],"category_scores_gemma":[0.0006555567,0.00004869619,0.0002342513,0.0001908516,0.0001437233,0.00006727561,0.0000916663,0.0004650749,0.0001867671],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003637867,"about_ca_system_score_gemma":0.0005044321,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00066111,"about_ca_topic_score_gemma":0.002534134,"domain_scores_codex":[0.9998955,0.00005453758,0.000006843511,0.00001048376,0.00001906944,0.00001369559],"domain_scores_gemma":[0.9997992,0.00005661749,0.00006066748,0.000009145193,0.00001124039,0.00006322049],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.09316611,0.003181626,0.02653037,0.002937956,0.0006672448,0.00137892,0.0001260863,0.002729033,0.0263769,0.0009908185,0.009703343,0.8322117],"study_design_scores_gemma":[0.1740306,0.3709463,0.2839016,0.002593921,0.003301729,0.01174921,0.0001861406,0.005363714,0.02061327,0.00287217,0.1243619,0.00007946334],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9187503,0.07183526,0.0009786231,0.001252609,0.000334426,0.0006355447,0.0001947165,0.0000376614,0.005980925],"genre_scores_gemma":[0.9800788,0.0164077,0.001020561,0.0004416017,0.0001612594,0.0002056678,0.000210567,0.000004749157,0.00146924],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001867402,"threshold_uncertainty_score":0.006247103,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03438742929994011,"score_gpt":0.3506999515904616,"score_spread":0.3163125222905215,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}